Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $1,015.00 price target on the biopharmaceutical company’s stock.

A number of other research firms have also commented on REGN. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an overweight rating in a research note on Friday, August 2nd. Truist Financial reaffirmed a buy rating and set a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating on the stock in a report on Thursday, July 11th. Barclays upped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an overweight rating in a report on Friday, August 2nd. Finally, Piper Sandler lifted their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an overweight rating in a research note on Friday, August 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of Moderate Buy and an average target price of $1,111.30.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $1,138.81 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market cap of $125.48 billion, a price-to-earnings ratio of 33.64, a P/E/G ratio of 3.97 and a beta of 0.12. The stock’s fifty day moving average price is $1,129.45 and its two-hundred day moving average price is $1,029.70. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the company earned $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after acquiring an additional 91,956 shares during the period. Capital World Investors grew its position in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after purchasing an additional 23,146 shares during the period. Capital International Investors increased its stake in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Putnam Investments LLC raised its holdings in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after buying an additional 24,329 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.